Clinical Research Pharmacies and Clinical Trials - Permits and Ownership
SB778 creates a new regulatory category for “clinical research pharmacies” in Maryland and authorizes the State Board of Pharmacy to issue permits for them. To qualify, a pharmacy must operate exclusively in connection with scientific research under approved protocols, dispense only as part of that research, remain closed to the general public for retail pharmacy services, and comply with security, storage, and other standards set by the Board. The bill also directs the Board to adopt regulations covering operating standards, applications, suspension and revocation, and inspection procedures.
The bill further amends Maryland law to clarify that certain research-related activity is not the “practice of medicine” when conducted by a corporation or other legal entity under approved clinical-trial protocols, with medical decision-making performed by licensed individuals and no general practice of medicine outside the trial. It also allows health care providers to hold ownership interests in clinical research pharmacies under specified conditions, while restricting those owners from directing patients to a particular pharmacist or receiving referral remuneration. The bill states that ownership alone cannot be the sole basis for discipline, but it preserves the authority of health occupations boards to investigate unauthorized practice or other violations.
In practical terms, the bill changes the Health Occupations Article by adding definitions, creating a permit framework, and carving out exceptions to existing restrictions on pharmacy ownership and the practice of medicine. It affects the State Board of Pharmacy, other health occupations boards, health care providers, pharmacists, and entities conducting clinical trials or research-based drug compounding and dispensing. It also reinforces that clinical research pharmacies are distinct from ordinary retail pharmacies and are subject to specialized oversight.
The overall sentiment appears strongly favorable. The bill passed the Senate unanimously and the House by a wide margin, indicating broad bipartisan support for facilitating clinical research while maintaining regulatory safeguards. No committee transcript concerns are provided, and the voting history suggests the measure was viewed as a targeted modernization of pharmacy and clinical-trial law rather than a controversial overhaul.
The main points of potential contention are the ownership and conflict-of-interest provisions. The bill permits health care providers to own interests in clinical research pharmacies, but only if they do not steer patients to a specific pharmacy or receive referral payments, and they cannot serve as clinical investigators for protocols conducted by the pharmacy. Another possible concern is the balance between encouraging research innovation and preserving patient safety and professional independence, which is why the bill preserves board investigative authority and requires pharmacist oversight on-site.
SB778 amends the Health Occupations Article to establish a new clinical research pharmacy permit, define clinical research pharmacies and related terms, and create a regulatory framework for their operation. It also adds exceptions to existing law so that certain research-based clinical trial activity is not treated as the practice of medicine, and so that health care providers may own interests in clinical research pharmacies under limited conditions. The bill expands the State Board of Pharmacy’s rulemaking, inspection, and enforcement responsibilities and preserves the authority of other health occupations boards to investigate unauthorized practice or other violations.
The bill appears to have received broad, bipartisan support. It passed the Senate 42-0 and the House 124-6, suggesting that lawmakers generally viewed it as a practical measure to support clinical research and clarify legal boundaries for pharmacy ownership and clinical trials. No committee debate is available in the provided materials, but the voting record indicates little organized opposition.
The most notable issues are conflict-of-interest and professional-independence safeguards. The bill allows health care providers to own clinical research pharmacies, but only if they do not direct patients to a particular pharmacist or pharmacy, do not receive referral remuneration, and do not serve as clinical investigators for protocols conducted by the pharmacy. It also requires a licensed pharmacist to be on-site and responsible for compounding, dispensing, and oversight, reflecting concern that ownership structures should not compromise clinical judgment or create unauthorized practice issues.